Schließeit, Jana
Oertel, Frederike Cosima
Cooper, Graham
Brandt, Alexander U.
Bellmann-Strobl, Judith http://orcid.org/0000-0003-2615-1643
Funding for this research was provided by:
Charité
Article History
Received: 5 May 2020
Accepted: 30 October 2020
First Online: 13 November 2020
Compliance with ethical standards
:
: JS has nothing to disclose. FCO was employed by Nocturne, unrelated to this manuscript. GC received speaker honoraria from Merck and Bayer, unrelated to this work. AUB is the founder and holds shares in Motognosis and Nocturne. He is named as the inventor on several patent applications describing serum biomarkers for MS, perceptive visual computing for tracking of motor dysfunction, and OCT image analysis. JBS has received travel grants and speaking honoraria from Bayer Healthcare, Biogen Idec, Merck Serono, Sanofi Genzyme, Teva Pharmaceuticals, Roche, and Novartis all unrelated to this work.
: All participants gave written informed consent.
: Not applicable.
: The cohort studies (Berlin-CIS-COHORT, NCT01371071, and VIMS, EA1/182/10) were approved by the local ethics committee and conducted in accordance with the Declaration of Helsinki.